Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $90.00

Halozyme Therapeutics (NASDAQ:HALO) had its target price boosted by investment analysts at Benchmark from $75.00 to $90.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Benchmark’s target price would suggest a potential upside of 25.76% from the company’s previous close.

Other equities research analysts have also issued reports about the stock. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Tuesday, November 4th. The Goldman Sachs Group restated a “sell” rating and set a $56.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, February 10th. Finally, Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $78.56.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock traded down $1.67 on Thursday, hitting $71.56. 1,704,071 shares of the company’s stock were exchanged, compared to its average volume of 2,100,929. Halozyme Therapeutics has a 1 year low of $47.50 and a 1 year high of $82.22. The company has a 50-day simple moving average of $71.77 and a 200-day simple moving average of $70.27. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. The stock has a market capitalization of $8.42 billion, a PE ratio of 28.85, a PEG ratio of 0.33 and a beta of 0.97.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 105.87% and a net margin of 22.69%.The company had revenue of $451.77 million during the quarter, compared to the consensus estimate of $446.13 million. During the same period in the prior year, the business posted $1.26 earnings per share. Halozyme Therapeutics’s revenue for the quarter was up 51.6% compared to the same quarter last year. As a group, equities analysts anticipate that Halozyme Therapeutics will post 4.73 EPS for the current year.

Insider Activity

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $78.64, for a total transaction of $786,400.00. Following the completion of the transaction, the chief executive officer owned 708,719 shares in the company, valued at $55,733,662.16. This trade represents a 1.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the sale, the director directly owned 40,123 shares in the company, valued at $2,818,640.75. This trade represents a 4.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 49,398 shares of company stock worth $3,650,592 over the last ninety days. Insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of HALO. DLD Asset Management LP boosted its stake in shares of Halozyme Therapeutics by 20.0% during the 3rd quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock worth $2,200,200,000 after purchasing an additional 5,000,000 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in shares of Halozyme Therapeutics by 29.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock valued at $241,337,000 after buying an additional 749,484 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Halozyme Therapeutics by 1.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock valued at $141,613,000 after buying an additional 25,731 shares during the last quarter. Norges Bank purchased a new stake in shares of Halozyme Therapeutics in the fourth quarter worth approximately $128,201,000. Finally, William Blair Investment Management LLC purchased a new position in Halozyme Therapeutics during the 4th quarter valued at $124,031,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Company reported record full‑year 2025 total revenue of $1.397 billion and reiterated strong 2026 guidance (2026 revenue $1.71–$1.81B; adjusted EBITDA $1.125–$1.205B; non‑GAAP EPS $7.75–$8.25), which supports longer‑term earnings upside if execution continues. PR Newswire: Full Year 2025 Results
• Positive Sentiment: Wells Fargo raised its price target to $75 (from $65) and maintained an “equal weight” rating, signaling some analyst confidence in the company’s revenue/royalty momentum despite the near‑term earnings miss. Benzinga: Wells Fargo price target
• Positive Sentiment: Q4 revenue of ~$451.8M (+51.6% YoY) beat consensus, driven by higher royalties and product sales — evidence of continuing top‑line strength. Zacks: Q4 revenues and royalties
• Neutral Sentiment: Analyst views remain mixed: several buy ratings and high targets exist, but some lower targets (and an “equal weight” from Wells Fargo) show differing views on valuation and near‑term risk. Investors should watch analyst revisions. QuiverQuant: Analyst/target summary
• Neutral Sentiment: Earnings call transcript and slide deck are available for deeper read on the acquisition charges and margin outlook — worth reviewing to separate one‑time items from recurring cash earnings. Quarterly slide deck
• Negative Sentiment: Surprise Q4 EPS miss: GAAP EPS swung to a loss (reported EPS -$0.24 vs. street expectations ~+$1.92) largely from acquisition‑related charges and higher operating costs, prompting the immediate sell‑off. MarketWatch: Stock declines on surprise Q4 loss
• Negative Sentiment: Large insider selling activity noted in recent months may raise governance/flow concerns for some investors, and the balance‑sheet/ liability increases highlighted in filings could amplify near‑term volatility. QuiverQuant: Insider and balance sheet data

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.